AAN 2024 | HEP2: seizure frequency decreases over time in patients with treatment-resistant epilepsy
Jacqueline French, MD, NYU Comprehensive Epilepsy Center, New York, NY, discusses the Human Epilepsy Project 2 (HEP2) study, a multi-center study examining longitudinal seizure patterns in patients with treatment-resistant focal epilepsy. The study indicates a decline in seizure frequency over time, yet it remains uncertain whether this translates to improved quality of life (QoL). Prof. French emphasizes that therapies previously considered disease-modifying due to reduced seizure activity may not actually alter the course of the disease. To ascertain which drugs are genuinely disease-modifying, they must be compared to a control group. This interview took place at the American Academy of Neurology (AAN) Annual Meeting 2024 in Denver, CO.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Dr. French has received personal compensation for serving as an officer or member of the Board of Directors for Epilepsy Foundation. Dr. French has received personal compensation for serving as a Chief Medical/Innovation Officer with Epilepsy Foundation. Dr. French has a non-compensated relationship as a Consultant/Scientific Advisory Board with Angelini, Alterity Therapeutics Limited, Bright minds Biosciences, Cerecin Inc, Cognizance Biomarkers, Arvelle, Beacon biosignals, Biohaven Pharmaceuticals, Bloom Science Inc, BridgeBio Pharma Inc, Camp4 Therapeutics Corporation, Cerebral Therapeutics, Cerevel, Coda Biotherapeutics, Genentech Inc, Crossject, Eisai, Eliem Therapeutics, Encoded Therapeutics, iQure Pharma, Engrail, Epihunter, Epiminder, Epitel Inc, Equilibre BioPharmaceuticals, Greenwich Biosciences, Grin Therapeutics, GW Pharma, Janssen Pharmaceuticals, Jazz Pharmaceuticals, Knopp Biosciences, Lipocine, Longboard Pharmaceuticals, Lundbeck, Marinus, Modulight Bio, Leal therapeutics, Neumirna Therapeutics, Neurocrine, Neuroelectrics USA Corporation, Neuronetics Inc, Ono Pharmaceutical Co, Otsuka Pharmaceutical Development, Ovid Therapeutics Inc, Paladin Labs Inc, Rapport Therapeutics, Praxis, PureTech LTY Inc, SK Life Sciences, Stoke, Supernus, Takeda, UCB Inc, Ventus Therapeutics, Xenon, Korro Bio Inc, NeuroPro Therapeutics, Receptor, Sage Therpeutics, Third Rock Ventures, Vida Ventures Management, Pfizer, Agrithera Inc, Autifony therapeutics Unlimited, Baergic Bio. The institution of Dr French has received research support from Epilepsy Study Consortium/ Epilepsy Foundation (Funded by UCB), GW/One8 Foundation/FACES, NINDS, Xenon, Cerevel, FACES, UCB, Epilepsy Study Consortium.
